Biogen Idec to acquire full rights and control of TYSABRI® from Elan for upfront cash and contingent payments
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
List view / Grid view
6 February 2013 | By Biogen Idec
Biogen Idec has agreed to purchase Elan’s interest in TYSABRI...
16 January 2013 | By Biogen Idec
Biogen Idec and Elan have submitted applications to the U.S. FDA...
11 October 2012 | By Biogen Idec
Results from 11 company-sponsored TYSABRI presentations...
24 September 2012 | By Elan Corporation
Mr. Hasler is currently a non-executive director of the Company and he will retire from the board of directors of the Company...
18 May 2012 | By Biogen Idec / Elan Corporation plc
Use of biomarker has potential to advance personalised treatment for MS patients...
26 January 2012 | By Biogen Idec
Biogen Idec and Elan Corporation, plc announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for SPMS...
20 January 2012 | By Biogen Idec and Elan Corporation, plc
The U.S. FDA has approved a product label change for TYSABRI...
12 December 2011 | By Elan Corporation, plc
€3m grant to combine business & science disciplines at University College Dublin...
28 November 2011 | By F T I Consulting
World’s leading researchers work together on therapeutic advances in neuroscience...
9 May 2011 | By Elan Drug Technologies (EDT)
Alkermes will merge with EDT in a cash and stock transaction currently valued at approximately $960 million...
9 February 2011 | By Boehringer Ingelheim
Announcement covers global technical development and manufacturing for antibody-based therapeutics...